Publication:
Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions

dc.contributor.authorAKKİPRİK, MUSTAFA
dc.contributor.authorsAgirbasli, Mehmet; Goktay, Fatih; Peker, Irem; Gunes, Pembegul; Aker, Fugen Vardar; Akkiprik, Mustafa
dc.date.accessioned2022-03-12T22:23:56Z
dc.date.accessioned2026-01-11T07:11:34Z
dc.date.available2022-03-12T22:23:56Z
dc.date.issued2017
dc.description.abstractAimThrombosis and inflammation play an important role in pathophysiology of livedoid vasculopathy (LV). Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of fibrinolysis and is a pivotal modulator in a broad range of biological processes. MethodThe study specimens were retrospectively selected from archives of pathology department. We investigated PAI-1 mRNA expression in the paraffin blocks of patients with biopsy-proven LV and controls. We analyzed the presence of thrombus, fibrinoid necrosis, ulcer, and epidermal atrophy in study samples. The correlation between histologic findings and PAI-1 expression was investigated. ResultsAnalyses were performed in 14 LV patients (mean age 3120, 79% female) and 4 controls (mean age 64 +/- 19, 50% female). PAI-1 gene expression was significantly higher in LV compared to the control group (median 7.74 (Iqr:13.94) vs 1.0 (0.31)), P=.011. Histological analysis displayed that fibrinoid necrosis was present on all patients with LV, 61.5% displayed thrombus, 46.2% displayed ulcer, and 15.4% displayed epidermal atrophy. Overall, we did not observe any discerning difference in PAI-1 expression between the LV blocks with or without thrombus, fibrinoid necrosis, or epidermal atrophy, yet the LV specimens that displayed ulcer histologically had higher PAI-1 mRNA expression compared to those without ulcer (median 13.98 (Iqr:19.21) vs 2.86 (5.59)), (P=.046). ConclusionPAI-1 mRNA expression is significantly increased in cutaneous lesions of patients with LV. Histological finding of ulcer is associated with increased PAI-1 expression in LV specimen. In the current era of PAI-1 inhibitors, enhanced local PAI-1 expression can form a novel and local therapeutic target in LV.
dc.identifier.doi10.1111/1755-5922.12255
dc.identifier.eissn1755-5922
dc.identifier.issn1755-5914
dc.identifier.pubmed28186689
dc.identifier.urihttps://hdl.handle.net/11424/234615
dc.identifier.wosWOS:000401193000007
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofCARDIOVASCULAR THERAPEUTICS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectFibrinolysis
dc.subjectPlasminogen activator inhibitor 1
dc.subjectPlasminogen inactivators
dc.subjectThrombosis
dc.subjectTopical administration
dc.subjectVascular diseases
dc.subjectVASCULITIS
dc.subjectDISEASE
dc.subjectPAI-1
dc.subjectPOPULATION
dc.subjectMUTATION
dc.subjectLEIDEN
dc.titleEnhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions
dc.typearticle
dspace.entity.typePublication
oaire.citation.issue3
oaire.citation.titleCARDIOVASCULAR THERAPEUTICS
oaire.citation.volume35

Files